Ochi, Shinichiro http://orcid.org/0000-0003-2263-3477
Roy, Bhaskar
Prall, Kevin
Shelton, Richard C.
Dwivedi, Yogesh http://orcid.org/0000-0002-5359-4717
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH118884, R01MH107183)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 14 April 2023
Revised: 30 August 2023
Accepted: 8 September 2023
First Online: 21 September 2023
Competing interests
: RCS has received grant support from the National Institutes of Health, Patient-Centered Outcomes Research Institute, American Foundation for Suicide Prevention, Acadia Pharmaceuticals, Alkermes, Inc., Allergan, Plc, Alto Pharmaceuticals, Avanir Pharmaceuticals, Inc., Boehringer Ingelheim, Denovo Biopharma, Genomind, InMune Bio, Intra-cellular Therapies, Janssen Pharmaceuticals, LivaNova PLC, Navitor Pharmaceuticals, Neurocrine Biosciences, Neurorx, Novartis Pharmaceuticals, Otsuka Pharmaceutical Company, Sunovion Pharmaceuticals, and Takeda Pharmaceuticals. He has received consulting fees from Acadia Pharmaceuticals, Allergan, Plc, Alphasigma USA, Inc., Boehringer Ingelheim, Cerecor, Inc., Denovo Biopharma, Janssen Pharmaceuticals, Myriad Neuroscience, Neurorx, Novartis AG, Otsuka Pharmaceuticals, Seelos Therapeutics, Inc., Sunovion Pharmaceuticals, and Takeda Pharmaceuticals. Other authors report no conflict of interest.